204 related articles for article (PubMed ID: 33493138)
21. Bioinformatic mining and validation of the effects of ferroptosis regulators on the prognosis and progression of pancreatic adenocarcinoma.
Xu F; Zhang Z; Zhao Y; Zhou Y; Pei H; Bai L
Gene; 2021 Aug; 795():145804. PubMed ID: 34175402
[TBL] [Abstract][Full Text] [Related]
22. MiR-10b inhibits migration and invasion of pancreatic ductal adenocarcinoma via regulating E2F7.
Xu C; Qi X
J Clin Lab Anal; 2020 Oct; 34(10):e23442. PubMed ID: 32592206
[TBL] [Abstract][Full Text] [Related]
23. Prognostic Fifteen-Gene Signature for Early Stage Pancreatic Ductal Adenocarcinoma.
Chen DT; Davis-Yadley AH; Huang PY; Husain K; Centeno BA; Permuth-Wey J; Pimiento JM; Malafa M
PLoS One; 2015; 10(8):e0133562. PubMed ID: 26247463
[TBL] [Abstract][Full Text] [Related]
24. Integrated analysis identified the role of three family members of ARHGAP in pancreatic adenocarcinoma.
Fei H; Shi X; Sun D; Yang H; Wang D; Li K; Si X; Hu W
Sci Rep; 2024 May; 14(1):11790. PubMed ID: 38783033
[TBL] [Abstract][Full Text] [Related]
25. MicroRNA-203 expression as a new prognostic marker of pancreatic adenocarcinoma.
Ikenaga N; Ohuchida K; Mizumoto K; Yu J; Kayashima T; Sakai H; Fujita H; Nakata K; Tanaka M
Ann Surg Oncol; 2010 Dec; 17(12):3120-8. PubMed ID: 20652642
[TBL] [Abstract][Full Text] [Related]
26. GNG7 and ADCY1 as diagnostic and prognostic biomarkers for pancreatic adenocarcinoma through bioinformatic-based analyses.
Zhang Y; Yang J; Wang X; Li X
Sci Rep; 2021 Oct; 11(1):20441. PubMed ID: 34650124
[TBL] [Abstract][Full Text] [Related]
27. Development and validation of a novel glycolysis-related risk signature for predicting survival in pancreatic adenocarcinoma.
Li A; Hou S; Chen J; Jiang Y
Clin Chim Acta; 2021 Jul; 518():156-161. PubMed ID: 33775699
[TBL] [Abstract][Full Text] [Related]
28. Exploring the significance of novel immune-related gene signatures in the prognosis and immune features of pancreatic adenocarcinoma.
Chen B; Hu C; Jiang L; Xiang Z; Zuo Z; Lin Y; Liu C
Int Immunopharmacol; 2021 Mar; 92():107359. PubMed ID: 33465729
[TBL] [Abstract][Full Text] [Related]
29. Expression patterns and prognostic values of the
Jiang P; Zhang M; Gui L; Zhang K
J Int Med Res; 2020 Dec; 48(12):300060520930113. PubMed ID: 33290118
[TBL] [Abstract][Full Text] [Related]
30. Meta-analysis of transcriptome data identifies a novel 5-gene pancreatic adenocarcinoma classifier.
Bhasin MK; Ndebele K; Bucur O; Yee EU; Otu HH; Plati J; Bullock A; Gu X; Castan E; Zhang P; Najarian R; Muraru MS; Miksad R; Khosravi-Far R; Libermann TA
Oncotarget; 2016 Apr; 7(17):23263-81. PubMed ID: 26993610
[TBL] [Abstract][Full Text] [Related]
31. Linc00511 acts as a competing endogenous RNA to regulate VEGFA expression through sponging hsa-miR-29b-3p in pancreatic ductal adenocarcinoma.
Zhao X; Liu Y; Li Z; Zheng S; Wang Z; Li W; Bi Z; Li L; Jiang Y; Luo Y; Lin Q; Fu Z; Rufu C
J Cell Mol Med; 2018 Jan; 22(1):655-667. PubMed ID: 28984028
[TBL] [Abstract][Full Text] [Related]
32. Upregulated long noncoding RNA LINC01296 indicates a dismal prognosis for pancreatic ductal adenocarcinoma and promotes cell metastatic properties by affecting EMT.
Yuan Q; Zhang Y; Feng L; Jiang Y
J Cell Biochem; 2019 Jan; 120(1):552-561. PubMed ID: 30203487
[TBL] [Abstract][Full Text] [Related]
33. Osteopontin influences the invasiveness of pancreatic cancer cells and is increased in neoplastic and inflammatory conditions.
Kolb A; Kleeff J; Guweidhi A; Esposito I; Giese NA; Adwan H; Giese T; Büchler MW; Berger MR; Friess H
Cancer Biol Ther; 2005 Jul; 4(7):740-6. PubMed ID: 15970685
[TBL] [Abstract][Full Text] [Related]
34. Genome-Wide Analysis Identified a Number of Dysregulated Long Noncoding RNA (lncRNA) in Human Pancreatic Ductal Adenocarcinoma.
Hao S; Yao L; Huang J; He H; Yang F; Di Y; Jin C; Fu D
Technol Cancer Res Treat; 2018 Jan; 17():1533034617748429. PubMed ID: 29343207
[TBL] [Abstract][Full Text] [Related]
35. PCDH1, a poor prognostic biomarker and potential target for pancreatic adenocarcinoma metastatic therapy.
Du X; Yi X; Zou X; Chen Y; Tai Y; Ren X; He X
BMC Cancer; 2023 Nov; 23(1):1102. PubMed ID: 37957639
[TBL] [Abstract][Full Text] [Related]
36. Identification of therapeutic targets and prognostic biomarkers of the ephrin receptor subfamily in pancreatic adenocarcinoma.
Zou J; Zhang K; Zhu J; Tu C; Guo J
J Int Med Res; 2024 Jan; 52(1):3000605231218559. PubMed ID: 38180878
[TBL] [Abstract][Full Text] [Related]
37. COMMD7 functions as molecular target in pancreatic ductal adenocarcinoma.
You N; Li J; Gong Z; Huang X; Wang W; Wang L; Wu K; Zheng L
Mol Carcinog; 2017 Feb; 56(2):607-624. PubMed ID: 27350032
[TBL] [Abstract][Full Text] [Related]
38. PKM2 Promotes Cell Survival and Invasion Under Metabolic Stress by Enhancing Warburg Effect in Pancreatic Ductal Adenocarcinoma.
Li C; Zhao Z; Zhou Z; Liu R
Dig Dis Sci; 2016 Mar; 61(3):767-73. PubMed ID: 26500118
[TBL] [Abstract][Full Text] [Related]
39. PLAGL1 is associated with prognosis and cell proliferation in pancreatic adenocarcinoma.
Liang X; Fu Z; Tang L; Zheng M; Chen D; Liu A; Shi L; Yang L; Shao C; Dong X
BMC Gastroenterol; 2023 Jan; 23(1):2. PubMed ID: 36600208
[TBL] [Abstract][Full Text] [Related]
40. Prognostic significance of AGR2 in pancreatic ductal adenocarcinoma.
Riener MO; Pilarsky C; Gerhardt J; Grützmann R; Fritzsche FR; Bahra M; Weichert W; Kristiansen G
Histol Histopathol; 2009 Sep; 24(9):1121-8. PubMed ID: 19609859
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
